In postmenopausal women diagnosed with early stage hormonal receptor positive BC, neither VET nor MHT was associated with increased risk of recurrence or mortality. A subgroup analysis revealed an increased risk of recurrence, but not mortality in patients using AI. The gene discussed is NR4A1; the disease is breast cancer.